MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the ...

Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the ...

A new paper published in Science from the MacAskill lab in NPP, led by graduate student Karyna Mishchanchuk, shows that a part of the brain called the hippocampus is really important for a key ...

In other Bright Minds Biosciences news, major shareholder Cormorant Asset Management, Lp purchased 372,591 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was ...

SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical-stage pharmaceutical company developing innovative solutions for ...

Behind the Bell is an interview series featuring CEOs, executives or founders, live from MarketSite on a company’s listing day or milestone celebration—generally in the moments after ringing ...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has been assigned an average rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat.com reports.

The company's lead candidate, ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions ...

Greenwood, SC (29646) Today Cloudy with rain developing after midnight. Low around 45F. Winds SW at 5 to 10 mph. Chance of rain 90% ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

MBX Biosciences and Septerna Therapeutics have stirred the biotech industry and the hypoparathyroidism treatment space alike. U.S.-based MBX’s $187.7 million offering will fund its lead candidate MBX ...